55，Slichenmeyer WJ,Nelson WG,Slebos RJ,Loss of a p53-associated G1 checkpoint do not decrease cell survival following DNA damage.Cancer,1993,53:4164 被引量：1
6[1]Watanabe Y,et al. OK-432,Clinical,PP.120,1984,Editors:Hoshino,T. ,et al,Printed in Japan 被引量：1
7[2]Sawai,k.et al. The 14th International Congress of Chemotherapy. Kyoto, June, 1985. Atracts: P-29-53 被引量：1
8[3]Uchida,A. ,et al: Int.J.Cancer,31,1,1983.OK-432,A Streptococcal Preparation as a potent Biological Response Modifier. Editors:Ishida,N.,et al.PP44,1983,Printed in Japan 被引量：1
5Lombardi G, Zustovich F, Nicoletto MO, et al. Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches[J]. Am J Clin Oncol,2010,33(4) :420. 被引量：1
6Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions: version 5.0[M].Cochrane collaboration, 2008. 被引量：1
8Musani A. Treatment options for malignant pleural effusion[J]. Curr Opin Pulm Med, 2009,15(4) : 380. 被引量：1
9Kuzdzal J, Soja J, Szlubowski A, et al.Treatment of malignant pleural effusion[J]. Pneumonol Alergol Pol, 2003, 71(3-4) : 186. 被引量：1
10OSTROWSKI M J.An assessment of the longterm result of controlling the reaccumulation of malignant effusions using intracavity bleomycin[J].Cancer,1986,5:721-727. 被引量：1
